Brief: Clover Biopharmaceuticals Reports Clearance Of Study For Rsv Vaccine Candidate By FDA
24/03/2025 01:15
March 24 (Reuters) - Clover Biopharmaceuticals 2197.HK: ANNOUNCES U.S. IND CLEARANCE AND INITIATION OF REVACCINATION CLINICAL STUDY FOR RSV VACCINE CANDIDATE SCB-1019 BY US FDA Further company coverage: 2197.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune